These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

609 related items for PubMed ID: 33949694

  • 21. Development and validation of a nomogram for predicting the likelihood of metastasis in prostate cancer patients undergoing Ga-68 PSMA PET/CT due to biochemical recurrence.
    Coskun N, Kartal MO, Erdogan AS, Ozdemir E.
    Nucl Med Commun; 2022 Aug 01; 43(8):952-958. PubMed ID: 35661662
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study.
    Meijer D, van Leeuwen PJ, Roberts MJ, Siriwardana AR, Morton A, Yaxley JW, Samaratunga H, Emmett L, van de Ven PM, van der Poel HG, Donswijk ML, Boellaard TN, Schoots IG, Oprea-Lager DE, Coughlin GD, Vis AN.
    Eur Urol; 2021 Aug 01; 80(2):234-242. PubMed ID: 34024652
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Development and External Validation of a Novel Nomogram to Predict the Probability of Pelvic Lymph-node Metastases in Prostate Cancer Patients Using Magnetic Resonance Imaging and Molecular Imaging with Prostate-specific Membrane Antigen Positron Emission Tomography.
    Vis AN, Meijer D, Roberts MJ, Siriwardana AR, Morton A, Yaxley JW, Samaratunga H, Emmett L, van de Ven PM, Heymans MW, Nieuwenhuijzen JA, van der Poel HG, Donswijk ML, Boellaard TN, Schoots IG, Stricker P, Haynes AM, Oprea-Lager DE, Coughlin GD, van Leeuwen PJ.
    Eur Urol Oncol; 2023 Dec 01; 6(6):553-563. PubMed ID: 37045707
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
    Sanli Y, Kuyumcu S, Sanli O, Buyukkaya F, İribaş A, Alcin G, Darendeliler E, Ozluk Y, Yildiz SO, Turkmen C.
    Ann Nucl Med; 2017 Nov 01; 31(9):709-717. PubMed ID: 28900854
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Lymph Node Involvement in Treatment-Naïve Prostate Cancer Patients: Correlation of PSMA PET/CT Imaging and Roach Formula in 280 Men in Radiotherapeutic Management.
    Koerber SA, Stach G, Kratochwil C, Haefner MF, Rathke H, Herfarth K, Kopka K, Holland-Letz T, Choyke PL, Haberkorn U, Debus J, Giesel FL.
    J Nucl Med; 2020 Jan 01; 61(1):46-50. PubMed ID: 31302638
    [Abstract] [Full Text] [Related]

  • 32. 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging Before Radical Prostatectomy: Central Review of Imaging and Comparison with Histopathology of Extended Lymphadenectomy.
    Esen T, Falay O, Tarim K, Armutlu A, Koseoglu E, Kilic M, Seymen H, Sarikaya AF, Kiremit MC, Balbay MD, Canda AE, Baydar DE, Kordan Y, Demirkol MO, Tilki D.
    Eur Urol Focus; 2021 Mar 01; 7(2):288-293. PubMed ID: 33509671
    [Abstract] [Full Text] [Related]

  • 33. Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.
    Budäus L, Leyh-Bannurah SR, Salomon G, Michl U, Heinzer H, Huland H, Graefen M, Steuber T, Rosenbaum C.
    Eur Urol; 2016 Mar 01; 69(3):393-6. PubMed ID: 26116958
    [Abstract] [Full Text] [Related]

  • 34. Incremental Impact of [68 Ga]Ga-PSMA-11 PET/CT in Primary N and M Staging of Prostate Cancer Prior to Curative-Intent Surgery: a Prospective Clinical Trial in Comparison with mpMRI.
    Szigeti F, Schweighofer-Zwink G, Meissnitzer M, Hauser-Kronberger C, Hitzl W, Kunit T, Forstner R, Pirich C, Beheshti M.
    Mol Imaging Biol; 2022 Feb 01; 24(1):50-59. PubMed ID: 34519966
    [Abstract] [Full Text] [Related]

  • 35. One-Stop-Shop Whole-Body 68Ga-PSMA-11 PET/MRI Compared with Clinical Nomograms for Preoperative T and N Staging of High-Risk Prostate Cancer.
    Thalgott M, Düwel C, Rauscher I, Heck MM, Haller B, Gafita A, Gschwend JE, Schwaiger M, Maurer T, Eiber M.
    J Nucl Med; 2018 Dec 01; 59(12):1850-1856. PubMed ID: 29794224
    [Abstract] [Full Text] [Related]

  • 36. Optimization of prostate cancer patient lymph node staging via the integration of neutrophil-lymphocyte ratios, platelet-lymphocyte ratios, and 68 Ga-PSMA-PET-derived SUVmax values.
    Wang Y, Tang Y, Gao X, Gan Y, Hu S, Chen MF, Cai Y.
    Prostate; 2022 Nov 01; 82(15):1415-1421. PubMed ID: 35860907
    [Abstract] [Full Text] [Related]

  • 37. Direct Patlak Reconstruction of [68Ga]Ga-PSMA PET for the Evaluation of Primary Prostate Cancer Prior Total Prostatectomy: Results of a Pilot Study.
    Rasul S, Geist BK, Einspieler H, Fajkovic H, Shariat SF, Schmitl S, Mitterhauser M, Bartosch R, Langsteger W, Baltzer PAT, Beyer T, Ferrara D, Haug AR, Hacker M, Rausch I.
    Int J Mol Sci; 2023 Sep 05; 24(18):. PubMed ID: 37761975
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.